Impact of Access Site on Periprocedural Bleeding and Cerebral and Coronary Events in High-Bleeding-Risk Percutaneous Coronary Intervention: Findings from the RIVA-PCI Trial.
Martin BorlichUwe ZeymerHarm WienbergenHans-Peter HobbachAlessandro CuneoRaffi BekeredjianOliver RitterBirgit HailerKlaus HerttingMarcus HennersdorfWerner ScholtzPeter LanzerHarald MudraMarkus SchweferPeter-Lothar SchwimmbeckChristoph LiebetrauHolger ThieleChristoph ClaasThomas RiemerRalf ZahnLeon IdenGert RichardtRalph ToelgPublished in: Cardiology and therapy (2023)
In HBR patients with AF undergoing PCI for acute or chronic coronary syndrome, the use of TRA might be associated with a decrease in in-hospital bleeding, while not increasing the risk of embolic or ischemic events compared to femoral access. Further studies are required to confirm these preliminary findings.
Keyphrases
- percutaneous coronary intervention
- atrial fibrillation
- coronary artery disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- antiplatelet therapy
- coronary artery bypass grafting
- acute coronary syndrome
- direct oral anticoagulants
- coronary artery
- catheter ablation
- heart failure
- coronary artery bypass
- healthcare
- clinical trial
- liver failure
- phase iii
- study protocol
- phase ii
- randomized controlled trial
- aortic stenosis
- subarachnoid hemorrhage
- ischemia reperfusion injury
- adverse drug
- left ventricular
- open label